Plain-English translation of NCT05686447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is testing a new blood screening method called MALDI-TOF mass spectrometry to detect multiple myeloma, a blood cancer that develops in bone marrow. The study compares how well this new method works compared to standard blood tests currently used. Researchers hope this method could become faster and more sensitive for catching the disease early.
Multiple myeloma is difficult to catch early, and doctors currently rely on several different blood tests that can take time to complete. This trial exists to see if the new testing method could help doctors identify the disease more quickly and accurately, especially in patients with very low levels of disease markers.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will donate a blood sample that researchers will analyze using the new mass spectrometry method. Your sample will be compared to samples from healthy volunteers to help researchers understand how well the new test can detect multiple myeloma. The study is enrolling up to 200 participants total and is currently recruiting.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Collaborators
National Natural Science Foundation of China
Enrollment target
~200 participants
Started
January 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nianyi Zeng
Zhujiang Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.